| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology and Experimental Therapeutics [C. F., M-N. K., S. S.] and Oncology Center [M. C.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Collaborative Research, Inc., Waltham, Massachusetts 02154 [A. M., O. M. F.]
Aldophosphamide (NSC 254), a putative key metabolite of cyclophosphamide, has now been isolated as a cyanohydrin derivative from an incubation mixture of cyclophosphamide with mouse liver microsomes in vitro and from the plasma of a cyclophosphamide-treated patient. The cyanohydrin has been shown to be identical with an authentic synthetic sample by mass spectrometry and combined gas chromatography-mass spectrometry.
1 This work was supported by Grants GM-21204 and CA-16783 from the USPHS and by National Cancer Institute Contract NO1-GM-60506.
2 Recipient of USPHS Research Career Development Award GM-70417.
3 Recipient of USPHS, MARC Fellowship GM-05709. On leave from Lincoln University, Lincoln, Pa.
4 Recipient of USPHS Research Career Development Award CA-00103.
Received 2/14/77. Accepted 4/29/77.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |